NCT04139304 - A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

July 31, 2029

Study Completion Date

July 31, 2030

Conditions

Plasmablastic LymphomaAnn Arbor Stage I Diffuse Large B-Cell LymphomaAnn Arbor Stage II Diffuse Large B-Cell LymphomaAnn Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell Lymphoma

Interventions

DRUG

Cyclophosphamide

Given IV

BIOLOGICAL

Daratumumab

Given IV

DRUG

Doxorubicin

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Etoposide

Given IV

DRUG

Prednisone

Given PO

DRUG

Vincristine

Given IV

DRUG

Vincristine Sulfate

Given IV

Trial Locations (8)

10021

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

19104

RECRUITING

University of Pennsylvania, Philadelphia

21231

RECRUITING

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27514

RECRUITING

University of North Carolina - Chapel Hill, Chapel Hill

33136

RECRUITING

University of Miami Miller School of Medicine, Miami

43210

RECRUITING

The Ohio State University, Columbus

60612

RECRUITING

University of Illinois at Chicago, Chicago

77030

RECRUITING

The University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

collaborator

Montefiore Medical Center

OTHER

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

AIDS and Cancer Specimen Resource

OTHER

collaborator

The Emmes Company, LLC

INDUSTRY

lead

AIDS Malignancy Consortium

NETWORK